HomeCompareAASCX vs JNJ

AASCX vs JNJ: Dividend Comparison 2026

AASCX yields 15.35% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AASCX wins by $34.7K in total portfolio value
10 years
AASCX
AASCX
● Live price
15.35%
Share price
$26.96
Annual div
$4.14
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$54.7K
Annual income
$3,959.20
Full AASCX calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — AASCX vs JNJ

📍 AASCX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAASCXJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AASCX + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AASCX pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AASCX
Annual income on $10K today (after 15% tax)
$1,305.13/yr
After 10yr DRIP, annual income (after tax)
$3,365.32/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, AASCX beats the other by $2,661.71/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AASCX + JNJ for your $10,000?

AASCX: 50%JNJ: 50%
100% JNJ50/50100% AASCX
Portfolio after 10yr
$37.4K
Annual income
$2,393.49/yr
Blended yield
6.41%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

AASCX
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AASCX buys
0
JNJ buys
0
No recent congressional trades found for AASCX or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAASCXJNJ
Forward yield15.35%3.36%
Annual dividend / share$4.14$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$54.7K$20.0K
Annual income after 10y$3,959.20$827.78
Total dividends collected$26.8K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AASCX vs JNJ ($10,000, DRIP)

YearAASCX PortfolioAASCX Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$12,235$1,535.45$10,676$355.77+$1.6KAASCX
2$14,848$1,755.78$11,407$389.39+$3.4KAASCX
3$17,878$1,991.25$12,198$426.53+$5.7KAASCX
4$21,371$2,240.83$13,056$467.62+$8.3KAASCX
5$25,370$2,503.32$13,987$513.12+$11.4KAASCX
6$29,923$2,777.37$14,998$563.56+$14.9KAASCX
7$35,079$3,061.53$16,098$619.52+$19.0KAASCX
8$40,889$3,354.27$17,295$681.69+$23.6KAASCX
9$47,405$3,654.03$18,599$750.82+$28.8KAASCX
10$54,683$3,959.20$20,022$827.78+$34.7KAASCX

AASCX vs JNJ: Complete Analysis 2026

AASCXStock

The fund invests at least 80% of its net assets (plus the amount of any borrowing for investment purposes) in equity securities of mid-sized companies. The Adviser focuses mainly on the equity securities of mid-sized U.S. companies which have market capitalizations equivalent to those included in widely known indices such as the Russell Midcap Index, S&P MidCap 400 Index, or the mid-sized company market capitalization classifications published by Lipper, Inc.

Full AASCX Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this AASCX vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AASCX vs SCHDAASCX vs JEPIAASCX vs OAASCX vs KOAASCX vs MAINAASCX vs ABBVAASCX vs MRKAASCX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.